EGFR and neoplasm: Finally, increased tumoral metabolic activity driven by EGFR alterations may also drive poor prognosis in patients with CD155 expression by enhancing glucose uptake and lipid synthesis, likely promoting tumor progression [17]; however, functional interplay between these oncogenes and CD155 remains unexplored.